Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.

CONCLUSION: The results of the present meta-analysis have confirmed the role of the CALR mutation in the diagnosis of, and as a prognostic tool for, PMF. Our results suggest that patients with the CALR mutation will have better overall survival than patients with the JAK2 mutation in a non-Asian population. PMID: 26935576 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26935576?dopt=Abstract

Source: Clinical Lymphoma and Myeloma - February 6, 2016 Category: Cancer & Oncology Authors: Kourie HR, Ameye L, Paesmans M, Bron D Tags: Clin Lymphoma Myeloma Leuk Source Type: research